At Aratana Therapeutics, Inc. (NASDAQ:PETX), the ratio of insider selling to insider buying over a quarter is running at 4. Could this be a sign something is bothering insiders? PETX recorded 4 sales count on the open market in the last three months. They sold nearly 77,607 shares while purchases amounted to zero shares that period. Looking even further back to 12 months, corporate insiders offloaded 220,000 shares when buyers snapped up 286,200 shares. The 12-month’s totals signify about a 0.77-to-1 sell/buy ratio.
St Peter Steven parted with a total of 46.09 thousand shares of Aratana Therapeutics, Inc. (PETX) at average share price of $5.85. This insider trade in the company took place on 12/17/2018. The total for the sales was set at $269.65 thousand. After this transaction, the PRESIDENT AND CEO account balance stood at 603.62 thousand shares. The stock lost -25.3 percent since that insider sale. On 11/07/2018, Heinen Ernst, Chief Development Officer, sold 19.31 thousand shares at a price per share of $6.95. This removed 134.19 thousand shares from the insider’s fortune and the stock saw a -37.12 percent retreat in value since the news became public. This transaction left 135.69 thousand shares in the Chief Development Officer account.
On 11/02/2018, Chief Development Officer Heinen Ernst performed a sale transaction worth $4.81 thousand. This sale at $6.95 each has eliminated 0.69 thousand shares from the insider’s portfolio position. Meanwhile, shares have recorded -37.12 percent decrease since the transaction was reported. The insider now is left with 155 thousand shares remaining in the account. St Peter Steven, who performs the PRESIDENT AND CEO job, sold 11.51 thousand shares for $67.47 thousand. The disposal occurred on 10/30/2018 was priced at $5.86 per share. The share price plunged -25.43 percent since the reporting date. St Peter Steven now left with a stake of 649.72 thousand PETX stock worth $2.84 million after the insider selling.
The 12-month median price target for Aratana Therapeutics, Inc. (PETX) assigned by the analysts stands at $8, which represents a return potential of 83.07 percent when compared to the closing price of the stock of $4.37 on Friday, January 11. The lowest price target for the stock is $5 — slightly more than 14.42 percent from PETX’s current share price. The stock will probably climb 89.24 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $10-month high price target. This represents a whopping 128.83 percent increase from where shares are trading today.
On momentum oscillators front, ‘RSI’ has touched 22.09 on daily chart, which may remain a cause for comfort. If the price breaks below $3.64 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $4.84 mark may result into a pull-back move towards $5.32 level. The stock is currently hovering around the first support level of $4. Below this, the next support is placed in the zone of $3.64. Till the time, the PETX stock trades above this level, bulls have nothing to fear.
Shares of Aratana Therapeutics, Inc. (PETX) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry PETX operates in has an average P/E of 31.12. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 7.06 on the Price-to-Sales ratio. Compare this with the industry average P/S of 4. 66.6 percent is the gross profit margin for Aratana Therapeutics, Inc. and operating margin sits at -46.3 percent. Along with this, the net profit margin is -52.9 percent.
On 11th of January, Aratana Therapeutics, Inc. (NASDAQ:PETX) shares ended lower after a volatile session. The shares dropped -1.58 points or -26.55 percent at $4.37 with a light trade volume of 6.796 million shares. After opening the session at $4.74, the shares went as high as $4.95 and as low as $4.11, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $289 million and now has 66.2 million shares outstanding. Aratana Therapeutics, Inc. (PETX) stock has lost -30.74 percent of market value in 21 trading days.
PETX stock has a trailing 3-year beta of 1.88, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$0.51 a share in the trailing twelve months. The stock’s value has fallen -28.71 percent year to date (YTD) against a decline of -16.76 percent in 12 month’s time. The company’s shares still trade -38.97 percent away from its 1-year high of $7.16 and 19.07 percent up from 52-week low of $3.67. The average consensus rating on the company is 1.5, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a buy.